• Marie-Christine Dombret, Khuder Alagha, Louis Philippe Boulet, Pierre Yves Brillet, Guy Joos, Michel Laviolette, Renaud Louis, Thierry Rochat, Paola Soccal, Michel Aubier, and Pascal Chanez.
• Dept of Respiratory Medicine, Bichat APHP, U700 INSERM University Hospitals Dept, Diderot University, Paris, France Dept of Respiratory Medicine, APHM, INSERM U1067 CNRS UMR 7333, Aix Marseille University, Marseille, FranceResearch Centre at the Institute of Cardiology and Respiratory Medicine, Laval University, Quebec, QC, CanadaDept of Radiology, Avicenne Public Hospital, Bobigny, France Dept of Respiratory Medicine, Ghent University Hospital, Ghent University, Ghent, BelgiumDept of Respiratory Medicine, Liege University Hospital, GIGAI3 Research Group, University of Liège, Liège, BelgiumDept of Respiratory Medicine, HUG Geneva, SwitzerlandBoth authors contributed equally Dept of Respiratory Medicine, Bichat APHP, U700 INSERM University Hospitals Dept, Diderot University, Paris, France Dept of Respiratory Medicine, APHM, INSERM U1067 CNRS UMR 7333, Aix Marseille University, Marseille, FranceResearch Centre at the Institute of Cardiology and Respiratory Medicine, Laval University, Quebec, QC, CanadaDept of Radiology, Avicenne Public Hospital, Bobigny, France Dept of Respiratory Medicine, Ghent University Hospital, Ghent University, Ghent, BelgiumDept of Respiratory Medicine, Liege University Hospital, GIGAI3 Research Group, University of Liège, Liège, BelgiumDept of Respiratory Medicine, HUG Geneva, SwitzerlandBoth authors contributed equally.
• Eur Respir Rev. 2014 Dec 1; 23 (134): 510-8.

AbstractBronchial thermoplasty is a young yet promising treatment for severe asthma whose benefit for long-term asthma control outweighs the short-term risk of deterioration and hospitalisation in the days following the treatment. It is an innovative treatment whose clinical efficacy and safety are beginning to be better understood. Since this is a device-based therapy, the overall evaluation of risk-benefit is unlike that of pharmaceutical products; safety aspects, regulatory requirements, study design and effect size assessment may be unfamiliar. The mechanisms of action and optimal patient selection need to be addressed in further rigorous clinical and scientific studies. Bronchial thermoplasty fits in perfectly with the movement to expand personalised medicine in the field of chronic airway disorders. This is a device-based complimentary asthma treatment that must be supported and developed in order to meet the unmet needs of modern severe asthma management. The mechanisms of action and the type of patients that benefit from bronchial thermoplasty are the most important challenges for bronchial thermoplasty in the future.©ERS 2014.

24 keywords...

hide…